Arecor Therapeutics PLC ARECOR GRANTED EUROPEAN PATENTS (3281V)
09 August 2022 - 4:00PM
UK Regulatory
TIDMAREC
RNS Number : 3281V
Arecor Therapeutics PLC
09 August 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR GRANTED EUROPEAN PATENTS PROTECTING PROPRIETARY
FORMULATIONS OF
HIGH CONCENTRATION HUMIRA(R) BIOSIMILAR
- Patents demonstrate strength of innovative Arestat(TM)
technology and its potential in development of enhanced
formulations of high value biologics
- Further strengthens Group's extensive patent portfolio
protecting its proprietary Arestat(TM) technology and proprietary
products
Cambridge, UK, 9 August 2022: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, is pleased to announce that the European
Patent Office has granted two patents ( EP3592383B1 and
EP3592385B1) protecting the Group's novel formulations of
high-concentration adalimumab until 2038.
Adalimumab, sold by AbbVie under the brand name Humira (R) , has
been a blockbuster monoclonal antibody product since its launch in
2003, indicated for a number of inflammatory diseases such as
rheumatoid arthritis and Crohn's disease. Global sales of Humira
increased by 4% in 2021 with total sales reported as $21bn(1) .
Several biosimilar versions of adalimumab have also entered the
European market since 2018 and are due to be launched in the US in
2023.
Humira (R) was originally approved as a 50 mg/mL adalimumab
product comprising citrate as a key formulation ingredient. An
improved product was subsequently launched by AbbVie with a high
adalimumab concentration (100 mg/mL) in the absence of citrate,
resulting in less injection site-related pain and providing greater
patient convenience due to the lower injection volumes. The market
for high-concentration adalimumab has been steadily increasing both
in the US and in Europe with high-concentration adalimumab now
representing about 80% of the total US market(2) .
Formulating a high concentration version of adalimumab is
technically challenging and further complicated by a complex patent
landscape surrounding adalimumab formulations. Using its
proprietary Arestat (TM) technology, Arecor has developed novel
formulations enabling a high-concentration adalimumab product (100
mg/mL or higher) with excellent stability. The two granted European
patents protect the novel design space enabling these formulations.
Corresponding patents in the US are expected to be granted later in
2022.
Sarah Howell, CEO of Arecor, commented : "These European patents
for high-concentration adalimumab are an important addition to
Arecor's product patent portfolio and provide further proof of the
potential of our Arestat(TM) technology in the development of
enhanced biologic products, including high value biosimilars.
"We have been very successful in applying the technology
platform to develop enhanced versions of existing products with key
enabling features, within our own In-house portfolio of proprietary
products and with leading healthcare companies through our
technology partnerships. The biologics field is one in which we
have considerable experience, as demonstrated by the novel and
differentiated formulation of AT220, a separate biosimilar product
in our current partnered programmes, formulated by Arecor and
licensed to one of our global pharmaceutical partners, which is now
in late-stage development."
Arecor has invested in building a strong patent portfolio to
protect the Arestat(TM) technology platform and its proprietary
pipeline products. The Group's intellectual property (IP) portfolio
currently comprises 36 patent families, including >50 granted
patents in Europe, the US and in other key territories. As part of
this strategy, Arecor has been developing robust IP directed to the
novel compositions of differentiated therapeutic products that
offer greater convenience of use for patients or healthcare
professionals. EP3592383B1 and EP3592385B1 represent a growing
number of the Group's patents in this area.
1. AbbVie Form 10-K 2021 p41
2.
https://www.centerforbiosimilars.com/view/samsung-bioepis-and-organiz-seek-to-enter-the-market-for-high-concentration-adalimumab
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arestat(TM)
Arecor's Arestat(TM) technology enables superior product
profiles across a broad range of therapies, including various types
of biopharmaceuticals and specialty hospital products. In addition
to its internal portfolio of superior proprietary products in
diabetes and other indications, Arecor leverages the Arestat(TM)
technology in partnerships with leading pharmaceutical and
biotechnology companies to deliver enhanced formulations of their
therapeutic products under a technology licensing model .
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUWVRRUKUWRUR
(END) Dow Jones Newswires
August 09, 2022 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024
